Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer’s deal announced two weeks earlier.

China's biotech sector is on a tear. The Hang Seng Biotech Index has climbed over 60% since Januaryhandily beating China tech ...

US drugmakers are betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.

In a resounding vote of confidence in China's biotechnology sector, leading global pharmaceutical companies are striking multibillion-dollar deals for innovative therapies developed by Chinese firms.

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD ...

The rally in the sector this year outpaces the 17% gain in China’s tech stocks that was driven by the release of DeepSeek’s ...

3SBio also teamed up with Sichuan Biokin Pharmaceutical (688506.SH) in February this year for clinical trials on the use of SSGJ-707 combined with an antibody drug conjugate, EGFR/HER3, that ...